Obesity market set for huge growth

The market for obesity treatments will grow five-fold by 2016, according to research firm Decision Resources.

The category, worth an estimated $478 million in 2006, will grow to $2.7 billion by 2016 in the US, UK, France, Germany, Italy, Spain and Japan, the firm projected. Growth will be most rapid in the US, where sales will increase from $222 million in 2006 to nearly $2 billion in 2016. 

Market growth will be fueled by a number of therapies, the report said, including from Arena Pharmaceuticals' lorcaserin and Amylin's pramlintide/leptin combo, expected to launch in major markets by 2011. The report anticipates 80% of the market switching to those and other therapies with novel mechanisms of action. However, the study's authors, citing the case of Sanofi-Aventis' Acomplia (rimonabant), caution that FDA's wariness toward new drugs in the category could slow growth and note that similar safety concerns could plague Merck's taranabant and Pfizer's CP-945598, which belong to the same drug class as rimonabant. 
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.